Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
Main Authors: | Yurie Kobashi, Makoto Watanabe, Hideaki Kimura, Asaka Higuchi, Akihiko Ozaki |
---|---|
Format: | Article |
Language: | English |
Published: |
Kerman University of Medical Sciences
2019-10-01
|
Series: | International Journal of Health Policy and Management |
Subjects: | |
Online Access: | https://www.ijhpm.com/article_3650_a81eb96d896a2cd63e68b437cc222169.pdf |
Similar Items
-
Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019
by: Anju Murayama, et al.
Published: (2023-01-01) -
Characteristics and Distribution of Scholarship Donations From Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A Cross-sectional Analysis
by: Anju Murayama, et al.
Published: (2023-12-01) -
Getting value today and incentivising for the future: Pharmaceutical development and healthcare policies
by: Kasper Munk Johannesen, et al.
Published: (2015-05-01) -
Impact of US industry payment disclosure laws on payments to surgeons: a natural experiment
by: Taeho Greg Rhee, et al.
Published: (2020-01-01) -
Regulating the relationship between physicians and pharmaceutical companies: a qualitative and descriptive analysis of the impact of Israeli legislation
by: Rachel Nissanholtz-Gannot, et al.
Published: (2017-09-01)